



Legislative Updates as of 06/05/2026

Policy Update

Federal and state policy activity continues to move quickly, with several developments important to the life sciences community.

Last week, the Office of Management and Budget released a [proposed rule](#) that would significantly change how federal grants and cooperative agreements are awarded, managed, and terminated. If finalized, the rule would revise the Uniform Guidance framework and could allow grants to be terminated for policy reasons, add new administrative requirements, and codify limits on certain racial, ethnic, and gender-related research. [Public comments are due July 13, and OMB intends for the rule to take effect October 1.](#)

On Capitol Hill, the House Labor-HHS Appropriations Subcommittee released its FY27 bill text ahead of markup. The proposal rejects many of the deep cuts included in the president's budget request and includes an approximately \$100 million increase for NIH. ARPA-H would be flat-funded, while CDC would see a substantial reduction and funding would be eliminated for AHRQ and the Patient-Centered Outcomes Research Institute. We encourage members to stay engaged and make their voices heard. [Visit the Georgia Life Sciences Action Center](#) to submit comments.

At the state level, Governor Brian Kemp has issued a formal [proclamation convening the Georgia General Assembly](#) in special session beginning June 17, 2026. The agenda includes redistricting for Georgia's congressional, state Senate, and state House districts; addressing changes to certain election code provisions; enacting local legislation; ratifying the Governor's executive order suspending motor fuel and aviation gasoline taxes; and confirming certain state appointments.

GLS Members Only: GBG Monthly Federal Funding Report Call

Don't miss the monthly GBG Report call, held every third Thursday at 12 PM ET. These sessions provide updates on the latest federal funding opportunities and insights to help companies navigate and secure non-dilutive capital. GLS partner G2G has helped raise over \$612M and brings deep expertise in supporting innovation and commercialization. Interested? Contact Stacey Bowlin at Sbowlin@galifesciences.org.

Georgia Life Sciences is the leading advocate for the state's life sciences sector. Our team works on behalf of our members to advance policies that support innovation and growth—advocating for federal funding that drives research and enables the approval of new therapies; a fair reimbursement and pricing landscape to ensure patient access to life-saving medicines; continued investment in research and pandemic preparedness; strong intellectual property protections that reward innovation; a business-friendly tax environment that allows companies to thrive and grow; and expanded loan guarantees and grant programs to improve access to capital, including for agricultural and energy biotechnology.